Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Assouline

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin LymphomaSarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Cancer|November 14, 2018
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemiaAdi J Klil-Drori, Hui Yin, Laurent Azoulay, et al.
American Journal of Hematology|July 4, 2017
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular responseAdi J Klil-Drori, Hui Yin, Laurent Azoulay, et al.
Leukemia Research|September 1, 2023
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapyFatima M Khadadah, Sonia Cerquozzi, Harold J Olney, et al.
Leukemia & Lymphoma|August 12, 2024
Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective studyAndrée-Anne Pelland, Xavier Deschênes-Simard, Xavier Savard, et al.
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Blood Advances|February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformationKatharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphomaM Dreyling, F Morschhauser, K Bouabdallah, et al.
Blood|December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomasStephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
British Journal of Haematology|December 4, 2025
Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysisMaria Agustina Perusini, Ana Flavia Patiño, Claire Andrews, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin LymphomaSarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Cancer|November 14, 2018
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemiaAdi J Klil-Drori, Hui Yin, Laurent Azoulay, et al.
American Journal of Hematology|July 4, 2017
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular responseAdi J Klil-Drori, Hui Yin, Laurent Azoulay, et al.
Leukemia Research|September 1, 2023
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapyFatima M Khadadah, Sonia Cerquozzi, Harold J Olney, et al.
Leukemia & Lymphoma|August 12, 2024
Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective studyAndrée-Anne Pelland, Xavier Deschênes-Simard, Xavier Savard, et al.
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Blood Advances|February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformationKatharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphomaM Dreyling, F Morschhauser, K Bouabdallah, et al.
Blood|December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomasStephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
British Journal of Haematology|December 4, 2025
Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysisMaria Agustina Perusini, Ana Flavia Patiño, Claire Andrews, et al.
Pageof 5